Search

Omeros Corp

Open

SectorGezondheidszorg

17.75 -3.32

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.78

Max

18.51

Belangrijke statistieken

By Trading Economics

Inkomsten

-38M

13M

Verkoop

19M

29M

K/W

Sectorgemiddelde

10.582

56.432

EPS

0.02

Winstmarge

46.381

Werknemers

175

EBITDA

-40M

18M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+78.86% upside

Dividenden

By Acuity

Volgende Winsten

12 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

281M

1.3B

Vorige openingsprijs

21.07

Vorige sluitingsprijs

17.75

Nieuwssentiment

By Acuity

34%

66%

68 / 339 Rangschikking in Healthcare

Omeros Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 sep 2026, 20:08 UTC

Omeros Corp is advancing sharply in Thursday's trading, having risen as much as 7% earlier before pulling back slightly, reflecting strong overall market gains.

16 sep 2026, 19:36 UTC

Omeros Corp is trading higher, having peaked earlier in the day, though it remains below its 20-day moving average amid a broader trend of lower closes.

15 sep 2026, 20:51 UTC

Omeros Corp shares are lower in after-market hours, continuing a five-session decline amid broader market pressures and elevated crude oil prices.

14 sep 2026, 23:06 UTC

Omeros Corp shares are lower in after-market hours, continuing a trend of declines amid broader market pressure from rising crude oil prices.

10 sep 2026, 20:03 UTC

Omeros Corp shares are lower today, continuing a decline since Wednesday. Trading volume is notably high, reflecting increased investor activity.

3 sep 2026, 19:46 UTC

Omeros Corp shares are higher today, supported by a modest upward trend since Wednesday. Easing Treasury yields may contribute to positive market sentiment.

2 sep 2026, 23:01 UTC

Omeros Corp shares are lower in after-market hours, continuing a downward trend. No specific company news was identified to explain the movement.

1 sep 2026, 19:16 UTC

Omeros Corp shares are lower today, reflecting a decline since Monday's close amid rising global bond yields and inflationary pressures.

31 aug 2026, 23:16 UTC

Omeros Corp shares are higher in after-market trading. No specific news was identified to explain this movement, which appears independent of broader market trends.

28 aug 2026, 20:07 UTC

Omeros Corp shares are lower amid rising U.S. Treasury yields and inflation concerns. The stock peaked early but shifted to a downward trajectory.

27 aug 2026, 22:01 UTC

Omeros Corp shares are lower in after-market trading, reflecting unusual volatility amid broader market concerns over the Federal Reserve's monetary policy and inflation pressures.

26 aug 2026, 23:06 UTC

Omeros Corp shares are higher in after-market hours, with no specific news identified. The stock has gained significantly compared to last month's close.

25 aug 2026, 23:12 UTC

Omeros Corp shares are lower in after-market hours following an unusual trading session, with no specific company news identified to explain the decline.

21 aug 2026, 19:16 UTC

Omeros Corp shares are higher today, trading above their 20-day moving average, despite no specific news to explain the price action.

20 aug 2026, 23:32 UTC

Omeros Corp shares are lower in after-market trading, reversing from a high of 0.70% to a low of -1.99%. No specific news was identified.

19 aug 2026, 22:51 UTC

Omeros Corp shares are trading lower in after-market hours, reaching a session low without any specific news to explain the decline.

18 aug 2026, 23:16 UTC

Omeros Corp. shares are lower in after-market trading, retracing from earlier gains. This decline coincides with mixed performance in Asian markets amid global economic uncertainties.

17 aug 2026, 23:06 UTC

Omeros Corp shares are lower in after-market trading, reaching a low of -1.21% before partially recovering. The stock remains above its 20-day moving average.

15 aug 2026, 00:01 UTC

Omeros Corp shares are higher in after-market trading, reflecting positive momentum as they trade above their 20-day moving average.

14 aug 2026, 23:41 UTC

Omeros Corp shares are lower in after-market trading, reflecting broader market sentiment amid a surprise decline in U.S. retail sales for July.

13 aug 2026, 23:06 UTC

Omeros Corp shares are lower in after-market hours, following notable volatility without any specific company news to explain the decline.

12 aug 2026, 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

11 aug 2026, 23:41 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

10 aug 2026, 23:51 UTC

Omeros Corp shares are lower in after-market hours, influenced by a recent labor report indicating job losses and reduced Fed rate hike expectations.

8 aug 2026, 00:02 UTC

Omeros Corp shares are lower in after-market hours, showing notable volatility since Friday's close. The stock remains above its 20-day moving average.

7 aug 2026, 23:31 UTC

Omeros Corp shares are trading lower in after-market hours, despite strong performance in the broader market, particularly among major tech stocks.

6 aug 2026, 23:01 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified. Recent economic data may influence expectations of Federal Reserve tightening.

5 aug 2026, 23:51 UTC

Omeros Corp shares are higher in after-market trading. Broader market sentiment is influenced by disappointing ADP employment data as investors await Non-Farm Payrolls.

4 aug 2026, 23:02 UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

3 aug 2026, 23:11 UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

Peer Vergelijking

Prijswijziging

Omeros Corp Prognose

Koersdoel

By TipRanks

78.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 33 USD  78.86%

Hoogste 33 USD

Laagste 33 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Omeros Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Sentiment

By Acuity

68 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.